WHEN: Fri, 28. Oct. 2016AT: Schloss Beuggen 11WHERE: Rheinfelden, Germany
Today, advanced cell therapies founded on human embryonic and induced pluripotent stem cells have entered clinical evaluation. These resources are also being integrated in the drug discovery process to confirm causative roles of mutated genes in various diseases and discover new therapeutic drugs to ameliorate disease pathologies. The socioeconomic impact of ongoing and future accomplishments is critically reliant on interdisciplinary engagements between diverse stakeholders informing standards of practice, conduct and care and translating knowledge into real-world practice.
Drawing on the professional expertise of expert practitioners across the spectrum of stem cell science and toxicology, the mission of Building Bridges event is to promote the understanding of this field and network amongst participants. This should create new interdisciplinary opportunities to advance the safety, efficacy and impact of the emerging field of personalised medicine.
Costanza Rovida, REACH Mastery, Como
Maria Chatzou, Phd, Centre for Genomic Regulation, Barcelona
Selina Wray, PhD, UCL Institute of Neurology, London
Glyn Stacey, PhD, National Institute for Biological Standards and Control, Hertfordshire
Paul A. De Sousa, PhD, Centre for Clinical Brain Sciences, Edinburgh
Rex FitzGerald, PhD, Swiss Centre for Applied Human Toxicology, Basel
Tomo Saric, M.D., Ph.D., Institute for Neurophysiology, Cologne